WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report
We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period. Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2011-07, Vol.31 (7), p.2441-2445 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2445 |
|---|---|
| container_issue | 7 |
| container_start_page | 2441 |
| container_title | Anticancer research |
| container_volume | 31 |
| creator | DOHI, Satoshi OHNO, Satoshi OHNO, Yumiko TAKAKURA, Masahiro KYO, Satoru SOMA, Gen-Ichiro SUGIYAMA, Haruo INOUE, Masaki |
| description | We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_907178931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907178931</sourcerecordid><originalsourceid>FETCH-LOGICAL-p272t-e4995db0fbf86668c1510c2abf5b12078f6b2f089a697e8d3a9e56d7db29e4dc3</originalsourceid><addsrcrecordid>eNqF0MtKAzEUBuAgiq3VV5BsxNVAkpnc3JXipVBo0aq4kCGXE4hMp2MyFfTpHbDi0tXhcL7_LP4DNKZS00LykhyiMWGcFJIQPkInOb8RIoRW5TEaMapkSbkco9fnNcUr6ProAT8Z52IL-KE3NjbxCzyet30ybtgbwMsPk6Jp8cy0DhJemT5C2-OwTXg5pF7ApCs8Hc4Z8D1029SfoqNgmgxn-zlBjzfX69ldsVjezmfTRdExyfoCKq25tyTYoIQQylFOiWPGBm4pI1IFYVkgShuhJShfGg1ceOkt01B5V07Q5c_fLm3fd5D7ehOzg6YxLWx3udZEUql0Sf-VSnFNtGZkkOd7ubMb8HWX4sakz_q3uwFc7IHJzjQhDbXE_OeqiiulRfkNj4x3UQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>885909920</pqid></control><display><type>article</type><title>WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>DOHI, Satoshi ; OHNO, Satoshi ; OHNO, Yumiko ; TAKAKURA, Masahiro ; KYO, Satoru ; SOMA, Gen-Ichiro ; SUGIYAMA, Haruo ; INOUE, Masaki</creator><creatorcontrib>DOHI, Satoshi ; OHNO, Satoshi ; OHNO, Yumiko ; TAKAKURA, Masahiro ; KYO, Satoru ; SOMA, Gen-Ichiro ; SUGIYAMA, Haruo ; INOUE, Masaki</creatorcontrib><description>We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 21873157</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject><![CDATA[Adjuvants, Immunologic - administration & dosage ; Biological and medical sciences ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; Cancer Vaccines - administration & dosage ; Cancer Vaccines - therapeutic use ; Carboplatin - administration & dosage ; Clinical Trials, Phase II as Topic ; Combined Modality Therapy ; Cystadenocarcinoma, Serous - drug therapy ; Cystadenocarcinoma, Serous - secondary ; Cystadenocarcinoma, Serous - surgery ; Cystadenocarcinoma, Serous - therapy ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; HLA-A Antigens - administration & dosage ; HLA-A Antigens - immunology ; HLA-A24 Antigen ; Humans ; Immunotherapy, Active ; Medical sciences ; Membrane Proteins - blood ; Middle Aged ; Omentum - pathology ; Omentum - surgery ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - surgery ; Ovarian Neoplasms - therapy ; Paclitaxel - administration & dosage ; Peptide Fragments - administration & dosage ; Peptide Fragments - immunology ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - surgery ; Peritoneal Neoplasms - therapy ; Taxoids - administration & dosage ; Tumor Burden ; Tumors ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - therapeutic use ; WT1 Proteins - administration & dosage ; WT1 Proteins - immunology]]></subject><ispartof>Anticancer research, 2011-07, Vol.31 (7), p.2441-2445</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24458896$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21873157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DOHI, Satoshi</creatorcontrib><creatorcontrib>OHNO, Satoshi</creatorcontrib><creatorcontrib>OHNO, Yumiko</creatorcontrib><creatorcontrib>TAKAKURA, Masahiro</creatorcontrib><creatorcontrib>KYO, Satoru</creatorcontrib><creatorcontrib>SOMA, Gen-Ichiro</creatorcontrib><creatorcontrib>SUGIYAMA, Haruo</creatorcontrib><creatorcontrib>INOUE, Masaki</creatorcontrib><title>WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>Cancer Vaccines - administration & dosage</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Combined Modality Therapy</subject><subject>Cystadenocarcinoma, Serous - drug therapy</subject><subject>Cystadenocarcinoma, Serous - secondary</subject><subject>Cystadenocarcinoma, Serous - surgery</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>HLA-A Antigens - administration & dosage</subject><subject>HLA-A Antigens - immunology</subject><subject>HLA-A24 Antigen</subject><subject>Humans</subject><subject>Immunotherapy, Active</subject><subject>Medical sciences</subject><subject>Membrane Proteins - blood</subject><subject>Middle Aged</subject><subject>Omentum - pathology</subject><subject>Omentum - surgery</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Paclitaxel - administration & dosage</subject><subject>Peptide Fragments - administration & dosage</subject><subject>Peptide Fragments - immunology</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - surgery</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Taxoids - administration & dosage</subject><subject>Tumor Burden</subject><subject>Tumors</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - therapeutic use</subject><subject>WT1 Proteins - administration & dosage</subject><subject>WT1 Proteins - immunology</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0MtKAzEUBuAgiq3VV5BsxNVAkpnc3JXipVBo0aq4kCGXE4hMp2MyFfTpHbDi0tXhcL7_LP4DNKZS00LykhyiMWGcFJIQPkInOb8RIoRW5TEaMapkSbkco9fnNcUr6ProAT8Z52IL-KE3NjbxCzyet30ybtgbwMsPk6Jp8cy0DhJemT5C2-OwTXg5pF7ApCs8Hc4Z8D1029SfoqNgmgxn-zlBjzfX69ldsVjezmfTRdExyfoCKq25tyTYoIQQylFOiWPGBm4pI1IFYVkgShuhJShfGg1ceOkt01B5V07Q5c_fLm3fd5D7ehOzg6YxLWx3udZEUql0Sf-VSnFNtGZkkOd7ubMb8HWX4sakz_q3uwFc7IHJzjQhDbXE_OeqiiulRfkNj4x3UQ</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>DOHI, Satoshi</creator><creator>OHNO, Satoshi</creator><creator>OHNO, Yumiko</creator><creator>TAKAKURA, Masahiro</creator><creator>KYO, Satoru</creator><creator>SOMA, Gen-Ichiro</creator><creator>SUGIYAMA, Haruo</creator><creator>INOUE, Masaki</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20110701</creationdate><title>WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report</title><author>DOHI, Satoshi ; OHNO, Satoshi ; OHNO, Yumiko ; TAKAKURA, Masahiro ; KYO, Satoru ; SOMA, Gen-Ichiro ; SUGIYAMA, Haruo ; INOUE, Masaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p272t-e4995db0fbf86668c1510c2abf5b12078f6b2f089a697e8d3a9e56d7db29e4dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>Cancer Vaccines - administration & dosage</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Combined Modality Therapy</topic><topic>Cystadenocarcinoma, Serous - drug therapy</topic><topic>Cystadenocarcinoma, Serous - secondary</topic><topic>Cystadenocarcinoma, Serous - surgery</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>HLA-A Antigens - administration & dosage</topic><topic>HLA-A Antigens - immunology</topic><topic>HLA-A24 Antigen</topic><topic>Humans</topic><topic>Immunotherapy, Active</topic><topic>Medical sciences</topic><topic>Membrane Proteins - blood</topic><topic>Middle Aged</topic><topic>Omentum - pathology</topic><topic>Omentum - surgery</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Paclitaxel - administration & dosage</topic><topic>Peptide Fragments - administration & dosage</topic><topic>Peptide Fragments - immunology</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - surgery</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Taxoids - administration & dosage</topic><topic>Tumor Burden</topic><topic>Tumors</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - therapeutic use</topic><topic>WT1 Proteins - administration & dosage</topic><topic>WT1 Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOHI, Satoshi</creatorcontrib><creatorcontrib>OHNO, Satoshi</creatorcontrib><creatorcontrib>OHNO, Yumiko</creatorcontrib><creatorcontrib>TAKAKURA, Masahiro</creatorcontrib><creatorcontrib>KYO, Satoru</creatorcontrib><creatorcontrib>SOMA, Gen-Ichiro</creatorcontrib><creatorcontrib>SUGIYAMA, Haruo</creatorcontrib><creatorcontrib>INOUE, Masaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOHI, Satoshi</au><au>OHNO, Satoshi</au><au>OHNO, Yumiko</au><au>TAKAKURA, Masahiro</au><au>KYO, Satoru</au><au>SOMA, Gen-Ichiro</au><au>SUGIYAMA, Haruo</au><au>INOUE, Masaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>31</volume><issue>7</issue><spage>2441</spage><epage>2445</epage><pages>2441-2445</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>21873157</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2011-07, Vol.31 (7), p.2441-2445 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907178931 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adjuvants, Immunologic - administration & dosage Biological and medical sciences Biomarkers, Tumor - blood CA-125 Antigen - blood Cancer Vaccines - administration & dosage Cancer Vaccines - therapeutic use Carboplatin - administration & dosage Clinical Trials, Phase II as Topic Combined Modality Therapy Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - secondary Cystadenocarcinoma, Serous - surgery Cystadenocarcinoma, Serous - therapy Female Female genital diseases Gynecology. Andrology. Obstetrics HLA-A Antigens - administration & dosage HLA-A Antigens - immunology HLA-A24 Antigen Humans Immunotherapy, Active Medical sciences Membrane Proteins - blood Middle Aged Omentum - pathology Omentum - surgery Ovarian Neoplasms - drug therapy Ovarian Neoplasms - surgery Ovarian Neoplasms - therapy Paclitaxel - administration & dosage Peptide Fragments - administration & dosage Peptide Fragments - immunology Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Peritoneal Neoplasms - surgery Peritoneal Neoplasms - therapy Taxoids - administration & dosage Tumor Burden Tumors Vaccines, Subunit - administration & dosage Vaccines, Subunit - therapeutic use WT1 Proteins - administration & dosage WT1 Proteins - immunology |
| title | WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A39%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WT1%20Peptide%20Vaccine%20Stabilized%20Intractable%20Ovarian%20Cancer%20Patient%20for%20One%20Year:%20A%20Case%20Report&rft.jtitle=Anticancer%20research&rft.au=DOHI,%20Satoshi&rft.date=2011-07-01&rft.volume=31&rft.issue=7&rft.spage=2441&rft.epage=2445&rft.pages=2441-2445&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E907178931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=885909920&rft_id=info:pmid/21873157&rfr_iscdi=true |